Hemogenyx Pharmaceuticals

HEMO: 1.88 0.00 (0.00%) delayed: 24 Feb 2020, 16:57

Trade now
Bid Price 1.80 High Price 0.00
Ask Price 2.00 Low Price 0.00
Open Price 0.00 Spread 0.00%
Prev Close 1.90 Volume 0

Hemogenyx Pharmaceuticals Share Price

Historic - 6 months
>> Advanced Hemogenyx Pharmaceuticals Charts >>

Hemogenyx Pharmaceuticals Share Price Information

Name Hemogenyx Pharmaceuticals
Sector Biotechnology
Activites Hemogenyx Pharmaceuticals plc (formerly Silver Falcon plc) with its wholly-owned US operating subsidiaries, Hemogenyx LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility and a wholly-owned Belgian operating subsidiary, Hemogenyx-Cell SPRL, located in Liege. Hemogenyx is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx is developing two distinct and complementary products, as well as a platform technology that it uses as an engine for novel product development. For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risks of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is restricted to use only as a last resort. Hemogenyx's technology has the potential to enable many more patients suffering from devastating blood diseases such as leukemia and lymphoma, as well as severe autoimmune diseases such as multiple sclerosis, aplastic anemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation.
Index n/a
Latest Share Price (p) 0.00 Net Gearing (%) -18.30
Market Capitalisation (£m) 7.35 Gross Gearing (%) 58.30
Shares in issue (m) 397.25 Debt Ratio 55.02
P/E Ratio -4.51 Debt-to-Equity Ratio 0.88
Total dividends per share (p) 0.00 Assets / Equity Ratio 2.40
Dividend Yield (%) 0.00 Price to book value 7.66
Dividend Cover 0.00 ROCE (%) -71.36
Earning per share (p) -0.41 EPS Growth (%) 59.00
52-week high / low (p) 3.75 / 1.60 DPS Growth (%) n/a

Hemogenyx Pharmaceuticals Director Deals

Date Director Type Volume / Price Trade Value
03 Jul 2019 Dr Vladislav Sandler Award 1,066,667 @ 3.00p £32,000.01
12 Feb 2018 Adrian Beeston Buy 200,000 @ 2.10p £4,200.00
07 Feb 2018 Dr Vladislav Sandler Buy 26,800 @ 2.37p £635.16
11 Oct 2017 Adrian Beeston Buy 400,000 @ 2.96p £11,840.00
10 Oct 2017 Adrian Beeston Buy 317,683 @ 3.10p £9,848.17
>> More Hemogenyx Pharmaceuticals Director Deals >>

Hemogenyx Pharmaceuticals News

>> More Hemogenyx Pharmaceuticals News >>